论文部分内容阅读
目的探讨奥曲肽联合普萘洛尔治疗肝硬化上消化道出血的临床疗效。方法选取2013年12月—2015年12月横县人民医院收治的肝硬化上消化道出血患者120例,随机分为研究组与对照组,各60例。研究组给予奥曲肽联合普萘洛尔治疗,对照组给予奥曲肽治疗。观察两组患者临床疗效、止血时间、心率、中心静脉压、再出血发生率及不良反应发生率。结果研究组患者总有效率高于对照组,差异有统计学意义(P<0.05)。研究组止血时间短于对照组,心率低于对照组,中心静脉压高于对照组,差异有统计学意义(P<0.05)。研究组再出血发生率、不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论奥曲肽联合普萘洛尔治疗肝硬化上消化道出血的临床疗效确切,能有效缩短止血时间,降低再出血发生率及不良反应发生率。
Objective To investigate the clinical efficacy of octreotide combined with propranolol in the treatment of upper gastrointestinal bleeding in cirrhosis. Methods 120 patients with cirrhosis and upper gastrointestinal hemorrhage admitted in Hengxian People’s Hospital from December 2013 to December 2015 were randomly divided into study group and control group, with 60 cases in each group. The study group was given octreotide plus propranolol and the control group was given octreotide. Clinical efficacy, bleeding time, heart rate, central venous pressure, the incidence of rebleeding and the incidence of adverse reactions were observed in two groups. Results The total effective rate of study group was higher than that of control group, the difference was statistically significant (P <0.05). The bleeding time in the study group was shorter than that in the control group, the heart rate was lower than that in the control group, and the central venous pressure was higher than that in the control group. The difference was statistically significant (P <0.05). The incidence of rebleeding and adverse reactions in the study group was lower than that in the control group, with significant difference (P <0.05). Conclusion The clinical efficacy of octreotide combined with propranolol in the treatment of upper gastrointestinal hemorrhage with cirrhosis is definite. It can shorten the time of hemostasis, reduce the incidence of rebleeding and the incidence of adverse reactions.